Form 4: Citius Pharma Exec Extends Warrants, Details Options
Insider Transaction Report
Citius Pharmaceuticals' Vice Chairman Myron Z. Holubiak reported warrant term extensions and detailed various stock option holdings in a recent SEC filing.
Summary
- Myron Z. Holubiak, Vice Chairman and Director of Citius Pharmaceuticals, Inc. (CTXR), reported changes in his beneficial ownership of derivative securities.
- Two outstanding warrants were amended on August 8, 2025, to extend their termination dates by one year.
- A warrant for 31,373 shares with an exercise price of $28.75 had its expiration date extended from August 14, 2025, to August 14, 2026.
- Another warrant for 22,344 shares with an exercise price of $19.25 had its expiration date extended from September 27, 2025, to September 27, 2026.
- The filing also details various stock options held by Mr. Holubiak, including 14,000 shares granted on November 7, 2024, with a $9.5 exercise price, vesting over three years.
- All reported share amounts reflect a 1-for-25 reverse stock split effective November 22, 2024.
- Mr. Holubiak directly owns 79,690 shares of common stock.
Sentiment
Score: 6
Explanation: The filing indicates continued executive alignment through warrant extensions and new option grants, which is generally positive for investor confidence, though it does not involve direct share purchases. The extension of warrant terms provides more time for potential value realization.
Positives
- Extension of warrant expiration dates provides more time for the warrants to potentially become in-the-money, benefiting the holder.
- The reporting person continues to hold a significant number of stock options (107,667 shares directly), indicating ongoing alignment with shareholder interests and potential future upside.
- New stock option grants (e.g., 14,000 shares on November 7, 2024) incentivize continued service and performance from the executive.
Negatives
- No direct acquisition of common stock was reported in this filing, only adjustments to derivative holdings and option grants.
- The exercise prices of some warrants and options are significantly higher than current stock prices, indicating they are currently out-of-the-money.
Risks
- Vesting of certain stock options is contingent upon the Optionee providing Continuous Service to the Company as of each vesting date.
Future Outlook
The vesting schedules for certain stock options indicate future potential share acquisitions contingent on the reporting person's continuous service to the company.
Management Comments
- All share amounts reflect the 1-for-25 reverse stock split effective November 22, 2024.
- The Reporting Person disclaims beneficial ownership in these shares (referring to options held by daughter).
Industry Context
This filing is a standard insider transaction report (Form 4) for a pharmaceutical company executive, detailing changes in derivative holdings and stock option grants. Such filings provide transparency into executive compensation and their equity incentives, which is common practice across all industries, including pharmaceuticals.
Related Party Transactions
- Stock options for 3,000 shares (exercise price $9.5), 600 shares (exercise price $51), and 400 shares (exercise price $50) are held by the reporting person's daughter, with the reporting person disclaiming beneficial ownership.
Stakeholder Impact
- Shareholders: The extension of warrant terms and the granting of stock options align the interests of the Vice Chairman with shareholders, as his potential gains are tied to the company's stock performance.
- Employees: The vesting conditions tied to 'Continuous Service' incentivize the executive's ongoing commitment to the company.
Next Steps
- Vesting of 1/3 of 14,000 stock options on the one-year, two-year, and three-year anniversaries of the Vesting Commencement Date (granted November 7, 2024), contingent on continuous service.
- Vesting of 1/3 of 16,000 stock options on the one-year, two-year, and three-year anniversaries of the Vesting Commencement Date (granted October 10, 2023), contingent on continuous service.
- Vesting of 1/3 of 16,000 stock options on the one-year, two-year, and three-year anniversaries of the Vesting Commencement Date (granted October 4, 2022), contingent on continuous service.
Key Dates
| Date | Description |
|---|---|
| 2018-08-13 | Original issuance date of the warrant for 31,373 shares. |
| 2019-09-27 | Original issuance date of the warrant for 22,344 shares. |
| 2022-10-04 | Grant date for 16,000 stock options with a $31.25 exercise price. |
| 2023-10-10 | Grant date for 16,000 stock options with a $17.5 exercise price. |
| 2024-11-07 | Grant date for 14,000 stock options with a $9.5 exercise price. |
| 2024-11-22 | Effective date of the 1-for-25 reverse stock split. |
| 2025-08-08 | Date of earliest transaction reported, involving warrant amendments. |
| 2025-08-12 | Signature date of the reporting person. |
| 2025-08-14 | Original expiration date of the first warrant (31,373 shares) before amendment. |
| 2025-09-27 | Original expiration date of the second warrant (22,344 shares) before amendment. |
| 2025-10-01 | Expiration date for 1,067 stock options with a $202.5 exercise price. |
| 2026-08-14 | New expiration date of the first warrant (31,373 shares) after amendment. |
| 2026-09-27 | New expiration date of the second warrant (22,344 shares) after amendment. |
| 2027-09-13 | Expiration date for 1,600 stock options with an $86.25 exercise price. |
| 2028-09-04 | Expiration date for 6,000 stock options with a $40.5 exercise price. |
| 2029-10-08 | Expiration date for 7,000 stock options with a $16.75 exercise price. |
| 2030-10-06 | Expiration date for 8,000 stock options with a $25.25 exercise price. |
| 2031-07-22 | Expiration date for 12,000 stock options with a $50 exercise price (and 400 for daughter). |
| 2031-10-11 | Expiration date for 26,000 stock options with a $51 exercise price (and 600 for daughter). |
| 2032-10-04 | Expiration date for 16,000 stock options with a $31.25 exercise price. |
| 2033-10-10 | Expiration date for 16,000 stock options with a $17.5 exercise price. |
| 2034-11-07 | Expiration date for 14,000 stock options with a $9.5 exercise price (and 3,000 for daughter). |
Keywords
Citius Pharmaceuticals, CTXR, SEC Form 4, insider transaction, beneficial ownership, stock options, warrants, derivative securities, executive compensation, reverse stock split
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.